Viral vector manufacturing process: addressing bottlenecks with innovative solutions

Cell & Gene Therapy Insights 2022; 8(11), 1475–1485

DOI: 10.18609/cgti.2022.216

Published: 14 December 2022
Innovator Insight
Rachel Legmann

With increasing approvals of viral vector-based gene therapies, the industry is shifting its focus to the expansion of viral vector manufacturing to meet the demands of the growing number of therapies on the market. Continuous improvements in the efficiency of viral vector production, as well as optimization of complex bioproduction processes, are essential to meet demand and get lifesaving therapies to patients quickly. This must be carefully balanced with consistency and quality of the final product. In this article, multiple applications and technologies to address current manufacturing challenges and solutions to increase overall viral vector yield throughout development will be explored. Case studies will be presented to demonstrate the progress associated with process intensification and optimization from benchtop development to large-scale commercial manufacturing.